Journal of Clinical Apheresis最新文献

{"title":"Special Issue Abstracts from the American Society for Apheresis 46th Annual Meeting April 9–11, 2025","authors":"","doi":"10.1002/jca.70014","DOIUrl":"https://doi.org/10.1002/jca.70014","url":null,"abstract":"","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 S1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jca.70014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143786949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lipoprotein(a) Measurement in Lipoprotein Apheresis: Time to Change?","authors":"Carmen Corciulo,&nbsp;Beatrice Dal Pino,&nbsp;Francesco Sbrana,&nbsp;Federico Bigazzi","doi":"10.1002/jca.70018","DOIUrl":"https://doi.org/10.1002/jca.70018","url":null,"abstract":"<div>\u0000 \u0000 <p>The question of standardizing the measurement of lipoprotein(a) [Lp(a)] has been discussed for many years, but the unavailability of automated methods insensitive to the structural heterogeneity of Lp(a) and the transition to a new unit of measurement have delayed this process. The aim of this study is to compare, in subjects undergoing regular lipoprotein apheresis (LA) treatment (31 subjects, mean age 62 ± 11 years, female 7/31), Lp(a) measurements performed using routine polyclonal antibodies with a method that recognizes a single copy of apo(a) per molecule. This pilot study for adopting an assay insensitive to apo(a) size polymorphism showed a good match with the traditional method: correlations between pre-LA and post-LA measures show an <i>R</i>² of 0.89 and 0.76, respectively. Despite the interpretative problem caused by adopting different units of measurement, we believe that moving to an assay insensitive to the dimensional variation of apo(a) represents a necessary change to standardize, improve, and extend the accuracy and diagnostic power of Lp(a).</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143770102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Descriptive 5-Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA: A Multicenter Study of 390 Disease Episodes From 2017 to 2021","authors":"Jeremy W. Jacobs,&nbsp;Brian D. Adkins,&nbsp;Garrett S. Booth,&nbsp;Caroline G. Stanek,&nbsp;Elizabeth S. Allen,&nbsp;Brenda J. Grossman,&nbsp;Laura D. Stephens,&nbsp;Elizabeth P. Crowe,&nbsp;Laetitia Daou,&nbsp;Marisa B. Marques,&nbsp;Rance C. Siniard,&nbsp;Lisa R. Wallace,&nbsp;Chisa Yamada,&nbsp;Miriam Andrea Duque,&nbsp;Yanyun Wu,&nbsp;Omar Aljuboori,&nbsp;Thomas J. Harrington,&nbsp;Diana M. Byrnes,&nbsp;Quentin Eichbaum,&nbsp;Cristina A. Figueroa Villalba,&nbsp;Justin E. Juskewitch,&nbsp;Ellen Klapper,&nbsp;Ingrid Perez-Alvarez,&nbsp;Monica S. Klein,&nbsp;Fatima Aldarweesh,&nbsp;Rahaf Alkhateb,&nbsp;Meredith G. Parsons,&nbsp;Annette J. Schlueter,&nbsp;Christopher A. Tormey,&nbsp;Allison P. Wheeler,&nbsp;Amy A. Powers,&nbsp;Christopher B. Webb,&nbsp;Sean G. Yates,&nbsp;Evan M. Bloch,&nbsp;Jay S. Raval","doi":"10.1002/jca.70017","DOIUrl":"https://doi.org/10.1002/jca.70017","url":null,"abstract":"<p>Immune thrombotic thrombocytopenic purpura (iTTP) is characterized by microangiopathic hemolytic anemia, thrombocytopenia, and microvascular occlusion secondary to acquired ADAMTS13 deficiency. Contemporary data regarding iTTP treatment practices in the US, including the use of caplacizumab, are lacking. We aimed to characterize the demographics and therapies, including medications and apheresis practices, in patients with iTTP in the US. We retrospectively analyzed iTTP cases at 15 sites in the US that provide comprehensive care for patients with iTTP. The time-period assessed was from January 1, 2017 to December 31, 2021. Our primary objective was to analyze data by iTTP episode, inclusive of initial episodes and relapses. A total of 390 iTTP episodes were reported for 280 unique individuals (187 females, 93 males). Thirty-day mortality was 3.7% (14/374), and 6-month mortality was 7.4% (27/367). TPE details were reported for 343 episodes, among which 261 underwent at least one procedure (median 6, IQR 3–11). Among the 261 episodes with at least one therapeutic plasma exchange (TPE) performed, 82.0% (214/261) used only plasma. Caplacizumab was used either alone or in combination with other agents in 43 (11.0%) episodes. Management strategies for iTTP remain varied across centers in the US, with a variety of combinations for TPE replacement fluids and therapeutic agents, as well as limited use of caplacizumab. Further research and standardization of treatment regimens may further reduce mortality in this condition.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jca.70017","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143707372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Therapeutic Plasma Exchange-Containing Regimens on Donor Specific Antibodies in Patients With Antibody Mediated Rejection of Pulmonary Transplant","authors":"Jasmine M. Velez,&nbsp;Coral Mansfield,&nbsp;Dongfeng Chen,&nbsp;John M. Reynolds,&nbsp;Grace M. Lee","doi":"10.1002/jca.70016","DOIUrl":"https://doi.org/10.1002/jca.70016","url":null,"abstract":"<div>\u0000 \u0000 <p>Prior studies examining therapeutic plasma exchange (TPE)-containing regimens in pulmonary transplant antibody-mediated rejection (AMR) have been limited by sample size and inconsistent application of TPE. In this single-center, retrospective study, patients with pulmonary transplant AMR who received a TPE-containing treatment regimen were examined. Mean fluorescence intensity (MFI) and Class distribution of DSAs were examined before/after 5 TPE and again after 8 TPE in the subset of patients who received an extended course of TPE. Fifty-two patients who completed 5 TPE were included. Testing of serum at 1:1 and 1:16 prior to initiation of TPE demonstrated that Class II DSAs occurred more frequently and at a higher MFI compared to Class I DSAs. After completing 5 TPE, for both 1:1 and 1:16 testing, the MFI of DSAs decreased significantly regardless of Class. For 4 patients with persistent DSAs, extending the course of TPE to 8 procedures did not cause an additional significant decline in the MFI of DSAs. Four patients developed de novo DSAs during the course of 5 TPE. Development of de novo DSAs was not associated with plasma exposure during TPE and was associated with high morbidity. In conclusion, completion of 5 TPE during treatment for pulmonary transplant AMR is associated with significant declines in DSAs regardless of HLA Class. Extending the course of TPE for DSAs which persist despite 5 TPE may be of limited benefit. De novo development of DSAs during the course of 5 TPE is associated with poor outcomes.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143646091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Gender Composition of Invited Speakers and Session Chairs at American Society for Apheresis Annual Meetings Between 2019 and 2024","authors":"Jeremy W. Jacobs,&nbsp;Elizabeth S. Allen,&nbsp;Laura D. Stephens,&nbsp;Brian D. Adkins,&nbsp;Jennifer S. Woo,&nbsp;Allison P. Wheeler,&nbsp;Deva Sharma,&nbsp;Yvette M. Miller,&nbsp;Garrett S. Booth","doi":"10.1002/jca.70015","DOIUrl":"https://doi.org/10.1002/jca.70015","url":null,"abstract":"<p>Disparities persist throughout medicine, including among conference speakership invitations. The National Institutes of Health have highlighted the importance of diversity at academic conferences. We assessed the gender composition of speakers at the American Society for Apheresis (ASFA) annual meeting. We assessed all session chairs and speakers at the annual ASFA meeting from 2019 to 2024. Two authors independently assessed individuals' genders. The primary outcome was the gender composition of all session chairs and speakers by position. Subset analyzes were performed to assess the gender composition of unique individuals (i.e., examining the total number of unique men and women, independent of the number of sessions at which they spoke) and by professional degree. 820 positions (665 speaker positions and 155 chair positions) were identified; women comprised significantly more positions than men [64.3%, 528/820 (95% CI 61.1%–67.6%) vs. 35.6% 292/820 (32.4%–38.9%); <i>p</i> &lt; 0.0001]. 52.7% (432/820) of all session positions were held by physicians, with no significant difference in the gender composition [women 47.5%, 205/432 (42.8%–52.2%) vs. men 52.6%, 227/432 (47.8%–57.2%); <i>p</i> = 0.31]. When limited to unique physician individuals, women were significantly outnumbered by men [40.1%, 71/177 (33.2%–47.5%) vs. 59.9%, 106/177 (52.5%–66.8%); <i>p</i> = 0.01]. This analysis demonstrated mixed findings, with more women across all positions overall but significantly more men when limited to unique physicians. Diversity in conference positions begets a broader array of perspectives, knowledge, and expertise, and can aid in realizing greater diversity in related areas. Thus, academic conference diversity should be prioritized and thoughtfully pursued.</p>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jca.70015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143602586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Efgartigimod on Utilization of Therapeutic Plasma Exchange Procedures for Myasthenia Gravis in One Tertiary Medical Center","authors":"Ashley J. Crosby,&nbsp;Mariama Evans,&nbsp;Danielle L. V. Maracaja,&nbsp;Yara A. Park,&nbsp;James F. Howard Jr,&nbsp;Matthew S. Karafin","doi":"10.1002/jca.70010","DOIUrl":"https://doi.org/10.1002/jca.70010","url":null,"abstract":"<div>\u0000 \u0000 <p>Myasthenia gravis (MG) is an autoimmune disorder caused by autoantibodies against proteins of the neuromuscular junction, such as the acetylcholine receptor (AChR). While therapeutic plasma exchange (TPE) has been a standard chronic therapy for patients with poorly controlled MG, new medications have recently been approved by the FDA for such patients. We report the impact of a new therapy, efgartigimod, on the number of therapeutic plasma exchanges performed on patients with generalized MG in our apheresis unit. A retrospective chart review was performed for patients with MG between 2018–2019 (pre-efgartigimod) and 2022–2023 (post-efgartigimod). We evaluated any changes between the two periods, including the total number of MG patients, the proportion of TPEs that were performed for MG, and the proportion of inpatient TPEs for MG. A statistically significant reduction (<i>p</i> &lt; 0.0001) was observed in the proportion of total TPE procedures for MG between the two time periods. In AChR-antibody positive (AChR-Ab +) patients who received both inpatient and outpatient procedures, there was a significant increase in the proportion of inpatient procedures post-efgartigimod (<i>p</i> = 0.0035). Our study demonstrated a decrease in the overall use of chronic TPE for MG over the 2-year period following the release of efgartigimod. However, there will remain a role for TPE in the setting of acute MG flares, the inpatient setting, during pregnancy, and in those who do not tolerate the new medications.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143565028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Developing A Model to Predict Major Bleeding Among Hospitalized Patients Undergoing Therapeutic Plasma Exchange","authors":"Alexandre Soares Ferreira Junior,&nbsp;Morgana Pinheiro Maux Lessa,&nbsp;Kate Sanborn,&nbsp;Alexander Gordee,&nbsp;Maragatha Kuchibhatla,&nbsp;Matthew S. Karafin,&nbsp;Oluwatoyosi A. Onwuemene","doi":"10.1002/jca.70013","DOIUrl":"https://doi.org/10.1002/jca.70013","url":null,"abstract":"<div>\u0000 \u0000 <p>Although therapeutic plasma exchange (TPE) can be associated with bleeding, there are currently no known strategies to reliably predict bleeding risk. This study developed a TPE bleeding risk prediction model for hospitalized patients. To develop the prediction model, we undertook a secondary analysis of public use files from the Recipient Epidemiology and Donor Evaluation Study-III. First, we used a literature review to identify potential predictors. Second, we used Multiple Imputation by Chained Equations to impute variables with &lt; 30% missing data. Third, we performed a 10-fold Cross-Validated Least Absolute Shrinkage and Selection Operator to optimize variable selection. Finally, we fitted a logistic regression model. The model identified 10 unique predictors and seven interactions. Among those with the highest odds ratios (OR) were the following: &gt; 10 TPE procedures and antiplatelet agents (OR 3.26); nephrogenic systemic sclerosis (OR 3.15); and intensive care unit stay (OR 3.08). Among those with the lowest OR were the following: albumin-only TPE (OR 0.50); male sex (OR 0.82); and heart failure (OR 0.85). The model indicated an acceptable performance with a C-statistic of 0.71 (95% CI 0.699–0.717). A model to predict bleeding risk among hospitalized patients undergoing TPE identified key predictors and interactions. Although the model achieved acceptable performance, future studies are needed to validate and operationalize it.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"G-CSF Only Versus Chemotherapy and G-CSF Peripheral Blood Stem Cell Mobilization for Autologous Hematopoietic Stem Cell Transplant—Assessing a Change in Regime due to the COVID-19 Pandemic","authors":"Julia S. Wolf,&nbsp;Frances Seymour,&nbsp;Christopher Parrish,&nbsp;Thea Chandler,&nbsp;Matthew Holt,&nbsp;James Griffin,&nbsp;Marina Karakantza","doi":"10.1002/jca.70012","DOIUrl":"https://doi.org/10.1002/jca.70012","url":null,"abstract":"<div>\u0000 \u0000 <p>Autologous stem cell transplant (ASCT) requires the collection of hematopoietic progenitor cells, commonly by apheresis (HPC-A). These CD34+ cells can be mobilized using Granulocyte Colony Stimulating Factor (G-CSF) only or chemomobilization plus G-CSF. Both methods may additionally include Plerixafor. The emergence of COVID-19 led to recommendations for preferential G-CSF only mobilization. To assess the impact of this recommendation on HPC-A harvesting, we analyzed data from the NHS Blood and Transplant Stem Cell Collection Registry for 1342 patients undergoing 2431 HPC-A procedures between 01/01/2019 and 31/12/2021. We compared G-CSF only, cyclophosphamide plus G-CSF (Cyclo-G) and G-CSF plus alternative chemotherapy (Chemo+G) mobilization. The outcomes collected were pre-apheresis CD34+ count, CD34+ yield per procedure, total CD34+ yield, number of apheresis procedures required to achieve the CD34+ target, mobilization failure, and Plerixafor use (+P). In multiple myeloma (MM), Cyclo-G (+/−P) mobilization produced significantly higher CD34+ yields than G-CSF only (7.44 vs. 4.75 × 10⁶/kg; <i>p</i> &lt; 0.0001). In Hodgkin lymphoma (HL) there was no statistically significant difference between regimes (CD34+ yield 4.53 × 10⁶/kg with G-CSF only (+/−P), 5.52 × 10⁶/kg with Cyclo-G (+/−P), 4.32 × 10⁶/kg with Chemo+G (+/−P)). In Non-Hodgkin lymphoma (NHL), Chemo+G (+/−P) was the most successful regime (5.98 × 10⁶/kg vs. 3.7 × 10⁶/kg with G-CSF only (+/−P) vs. 3.69 × 10⁶/kg with Cyclo-G (+/−P); <i>p</i> &lt; 0.00001). On demand Plerixafor use resulted in &gt; 95% successful mobilization in MM and NHL. CD34+ yields are higher using Cyclo-G and Chemo+G in NHL. In MM, G-CSF only resulted in yields sufficient for at least one transplant. In HL, our data show no evidence to support the use of Cyclo-G over G-CSF only.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143530138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Adverse Reactions With Solvent/Detergent Treated Plasma Versus Untreated Plasma Use in Therapeutic Plasma Exchange in Pediatric Patients","authors":"Samantha Phou,&nbsp;Cari Berryhill,&nbsp;Frank Nizzi,&nbsp;Bryce Pasko","doi":"10.1002/jca.70011","DOIUrl":"https://doi.org/10.1002/jca.70011","url":null,"abstract":"<div>\u0000 \u0000 <p>Solvent/detergent treated plasma (SD plasma) use in therapeutic plasma exchange (TPE) in pediatric patients is not commonly reported. This study aimed to determine transfusion reaction rates using SD plasma and to compare transfusion reaction rates and adverse events when using SD plasma versus untreated plasma in pediatric TPE. A retrospective review was performed on TPE procedures performed at a single institution over a 3-year period. For each TPE procedure, replacement fluid was determined at the discretion of the transfusion medicine physician, consisting of either 5% albumin, untreated plasma, SD plasma, or a combination of untreated or SD plasma with 5% albumin. SD plasma was used in 51 TPE procedures performed on 17 patients. In comparison, untreated plasma was used in 254 procedures in 68 patients. Patient ages ranged from 6 days to 20 years old. With SD plasma use, 1 procedure (2% incidence) reported a non-severe allergic transfusion reaction, compared to 9 procedures (3.5% incidence) with untreated plasma use. These transfusion reaction rates were not statistically different (<i>p</i> = 0.7036, two-tailed Fisher's exact test). Circuit clotting issues were reported in one patient during two discrete TPE procedures utilizing untreated plasma. No other transfusion reactions or adverse events were reported. SD plasma used for TPE was well tolerated, with transfusion reaction rates similar to those observed in untreated plasma in our pediatric patients. SD plasma may be used for TPE in pediatric patients without apparent increased procedure-related risks or increased risks of transfusion reactions compared to untreated plasma.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 2","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143521986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nurse-Led Apheresis Service in a Pediatric Restructured Hospital: The Past, the Present, and the Future","authors":"Pham Thi Ngoc Anh,&nbsp;Xinni Zhong,&nbsp;Siew Ling Yvonne Lim,&nbsp;Puaness Wari Periakaruppan,&nbsp;Vijayakumari K.","doi":"10.1002/jca.70009","DOIUrl":"https://doi.org/10.1002/jca.70009","url":null,"abstract":"<div>\u0000 \u0000 <p>Apheresis nurses are well equipped with not only the critical thinking skills but also the important aspects of operating the apheresis machine. As the demand for advanced cellular therapies grew, there was a need to recruit and train more nurses to be competent in apheresis nursing. A new service model was evolved from a physician-led to a nurse-led apheresis service, which empowered the apheresis nurses to lead the service. Since the commencement of the nurse-led service, a total of 32 peripheral hematopoietic progenitor cells collections were documented, and the outcomes of the cell yield were tabulated to study the collection efficiency. Ninety-four percent of the targeted cell yield was achieved with no collections needing beyond 2 days of harvesting. No apheresis-related major adverse event was reported following the implementation of the new service model too.</p>\u0000 </div>","PeriodicalId":15390,"journal":{"name":"Journal of Clinical Apheresis","volume":"40 1","pages":""},"PeriodicalIF":1.4,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143447213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}